Ameliorative effect of selegiline in high fat diet induced obesity rat model: Possible role of dopaminergic pathway

Abstract

ObjectivesDopamine a neurotransmitter plays an important role in food regulation. Various reports revealed that suppression of dopamine results in pathological overeating. Monoamine oxidase type B (MAO-B) inhibitor selegiline (SG) increases the level of dopamine in the brain. Thus, the current study was designed to examine whether selegiline (SG) could attenuate the development of experimental obesity and to explore the possible involvement of dopamine in high fat diet (HFD) induced obesity. Materials and methodsCurrent study illustrates importance of administrating SG (10 and 20 mg kg−1 day−1, p. o.) alone and SG (20 mg kg−1 day−1, p. o) in combination with chlorpromazine (CPZ) (6 mg kg−1 day−1p.o) in obesity. The SG and its combination with CPZ were given orally for 6 weeks along with high fat diet to the obese rats. The body weight, feed intake (Kcal), weight and size of fat pads, levels of serum glucose, triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), very low-density lipoprotein VLDL and high density lipoproteins (HDL) were estimated as parameters of obesity. ResultsOral administration of SG (10 and 20 mg kg−1day−1) significantly reduced (p < 0.05) body weight gain, feed intake (Kcal), weight and size of fat pads, levels of serum glucose, TG, TC, LDL, VLDL in obese rats. Furthermore, Dopaminergic antagonist CPZ in combination with SG declines the beneficial effects of SG in obese rats. ConclusionThe present study demonstrates the involvement of dopaminergic pathway and beneficial effects of dopamine enhancer SG in HFD induced obesity.